RxDoctor Payments Data

Makayla Durrant, APRN

Family · Pickerington, OHNPI 1265190797

Payments from drug & device makers

$5,484in general payments, 2019–2025

Across 287 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$897
  • Takeda Pharmaceuticals U.S.A., Inc.$366
  • Sanofi$324
  • Regeneron Healthcare Solutions, Inc.$297
  • QOL Medical, LLC$261
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$5,463100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,484 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$37,113
Medicare patients
309
Services billed
1,655

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide93$77,855
CreonLipase/Protease/Amylase18$59,307
XifaxanRifaximin18$53,214
MovantikNaloxegol Oxalate15$6,298
Ondansetron Hcl16$6,281
Dexlansoprazole DrDexlansoprazole31$5,914
Pantoprazole Sodium221$2,840
Colestipol Hcl67$2,583
Dicyclomine Hcl136$2,239
Ursodiol12$1,910
Ondansetron OdtOndansetron55$1,621
Omeprazole141$1,553
Colesevelam Hcl13$1,242
Famotidine123$1,186
Lactulose19$708

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$1,787$137,162111 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$897$53,21418 claims
SandozLansoprazole$23$24911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.

Other family in Pickerington

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →